Newly developed glycogen synthase kinase-3 (GSK-3) inhibitors protect neuronal cells death in amyloid-beta induced cell model and in a transgenic mouse model of Alzheimer's disease

Biochemical and Biophysical Research Communications

Volumn 435, Issue 2, 2013, Pages 274-281

  Noh, Min Young ^a   Chun, Kwangwoo ^b   Kang, Byung Yong ^a   Kim, Heejaung ^a   Park, Ji Seon ^b   Lee, Han Chang ^b   Kim, Young Ha ^b   Ku, Saekwang ^c   Kim, Seung Hyun ^a  

^a Hanyang University College of Medicine   (South Korea)

^b Jeil Pharmaceutical Co Ltd   (South Korea)

^c Daegu Haany University   (South Korea)

Author keywords

Alzheimer's disease; Amyloid beta; GSK 3 inhibitor; TAU

Indexed keywords

2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; AMYLOID BETA PROTEIN; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; OLIGOMER; SERINE; TAU PROTEIN; THREONINE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SYNTHESIS; ENZYME ACTIVITY; HIPPOCAMPUS; IC 50; IMMUNOCYTOCHEMISTRY; MOUSE; NERVE CELL; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SHORT TERM MEMORY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOPTOSIS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOGEN SYNTHASE KINASE 3; MICE; MICE, TRANSGENIC; NEURONS; NEUROPROTECTIVE AGENTS; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

MUS; MUS MUSCULUS;

EID: 84878425040     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.04.065     Document Type: Article

References (31)

1. Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol. Med. 2002, 8:126-132.
2. Jope R.S., Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 2004, 29:95-102.
3. Martinez A., Castro A., Dorronsoro I., Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev. 2002, 22:373-384.
4. Cai Z., Zhao Y., Zhao B. Roles of glycogen synthase kinase 3 in Alzheimer's disease. Curr. Alzheimer Res. 2012, 9:864-879.
5. DaRocha-Souto B., Coma M., Perez-Nievas B.G., Scotton T.C., Siao M., Sanchez-Ferrer P., Hashimoto T., Fan Z., Hudry E., Barroeta I., Sereno L., Rodriguez M., Sanchez M.B., Hyman B.T., Gomez-Isla T. Activation of glycogen synthase kinase-3 beta mediates beta-amyloid induced neuritic damage in Alzheimer's disease. Neurobiol. Dis. 2012, 45:425-437.
6. Kwok J.B., Loy C.T., Hamilton G., Lau E., Hallupp M., Williams J., Owen M.J., Broe G.A., Tang N., Lam L., Powell J.F., Lovestone S., Schofield P.R. Glycogen synthase kinase-3beta and tau genes interact in Alzheimer's disease. Ann. Neurol. 2008, 64:446-454.
7. Hooper C., Killick R., Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J. Neurochem. 2008, 104:1433-1439.
8. Eldar-Finkelman H., Licht-Murava A., Pietrokovski S., Eisenstein M. Substrate competitive GSK-3 inhibitors - strategy and implications. Biochim. Biophys. Acta 1804, 2010:598-603.
9. Gong C.X., Iqbal K. Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr. Med. Chem. 2008, 15:2321-2328.
10. Hanger D.P., Noble W. Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation. Int. J. Alzheimers Dis. 2011, 2011:352805.
11. Young J.R., Huang S.X., Walsh T.F., Wyvratt M.J., Yang Y.T., Yudkovitz J.B., Cui J., Mount G.R., Ren R.N., Wu T.J., Shen X., Lyons K.A., Mao A.H., Carlin J.R., Karanam B.V., Vincent S.H., Cheng K., Goulet M.T. 2-Arylindoles as gonadotropin releasing hormone (GnRH) antagonists: optimization of the tryptamine side chain. Bioorg. Med. Chem. Lett. 2002, 12:827-832.
12. de Raemy-Schenk A.M., Trouble S., Gaillard P., Page P., Gotteland J.P., Scheer A., Lang P., Yeow K. A cellular assay for measuring the modulation of glucose production in H4IIE cells. Assay Drug Dev. Technol. 2006, 4:525-533.
13. Noh M.Y., Kim Y.S., Lee K.Y., Lee Y.J., Kim S.H., Yu H.J., Koh S.H. The early activation of PI3K strongly enhances the resistance of cortical neurons to hypoxic injury via the activation of downstream targets of the PI3K pathway and the normalization of the levels of PARP activity, ATP, and NAD(+). Mol. Neurobiol. 2013, 47:757-769.
14. Noh M.Y., Koh S.H., Kim Y., Kim H.Y., Cho G.W., Kim S.H. Neuroprotective effects of donepezil through inhibition of GSK-3 activity in amyloid-beta-induced neuronal cell death. J. Neurochem. 2009, 108:1116-1125.
15. Cho G.W., Noh M.Y., Kang B.Y., Ku I.W., Park J., Hong Y.H., Kim M.H., Kim S.H. Development of a cellular tau enzyme-linked immunosorbent assay method for screening GSK-3beta inhibitors. Assay Drug Dev. Technol. 2011, 9:503-513.
16. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
17. Onishi T., Iwashita H., Uno Y., Kunitomo J., Saitoh M., Kimura E., Fujita H., Uchiyama N., Kori M., Takizawa M. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S)-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease. J. Neurochem. 2011, 119:1330-1340.
18. Kim H.V., Kim H.Y., Ehrlich H.Y., Choi S.Y., Kim D.J., Kim Y. Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model. Amyloid 2013, 20:7-12.
19. Koh S.H., Noh M.Y., Kim S.H. Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3. Brain Res. 2008, 1188:254-262.
20. Berg S., Bergh M., Hellberg S., Hogdin K., Lo-Alfredsson Y., Soderman P., von Berg S., Weigelt T., Ormo M., Xue Y., Tucker J., Neelissen J., Jerning E., Nilsson Y., Bhat R. Discovery of novel potent and highly selective glycogen synthase kinase-3beta (GSK3beta) inhibitors for Alzheimer's disease: design, synthesis, and characterization of pyrazines. J. Med. Chem. 2012, 55:9107-9119.
21. Bhat R.V., Budd Haeberlein S.L., Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. J. Neurochem. 2004, 89:1313-1317.
22. Torrent L., Ferrer I. PP2A and Alzheimer disease. Curr. Alzheimer Res. 2012, 9:248-256.
23. Martinez A., Perez D.I. GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease?. J. Alzheimers Dis. 2008, 15:181-191.
24. Townsend M., Mehta T., Selkoe D.J. Soluble abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J. Biol. Chem. 2007, 282:33305-33312.
25. Lee H.K., Kumar P., Fu Q., Rosen K.M., Querfurth H.W. The insulin/Akt signaling pathway is targeted by intracellular beta-amyloid. Mol. Biol. Cell. 2009, 20:1533-1544.
26. Hoppe J.B., Frozza R.L., Horn A.P., Comiran R.A., Bernardi A., Campos M.M., Battastini A.M., Salbego C. Amyloid-beta neurotoxicity in organotypic culture is attenuated by melatonin: involvement of GSK-3beta, tau and neuroinflammation. J. Pineal Res. 2010, 48:230-238.
27. Toledo E.M., Inestrosa N.C. Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Mol. Psychiatry 2010, 15:272-285. 228.
28. Engel T., Goni-Oliver P., Lucas J.J., Avila J., Hernandez F. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J. Neurochem. 2006, 99:1445-1455.
29. Rockenstein E., Torrance M., Adame A., Mante M., Bar-on P., Rose J.B., Crews L., Masliah E. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J. Neurosci. 2007, 27:1981-1991.
30. Meijer L., Flajolet M., Greengard P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol. Sci. 2004, 25:471-480.
31. Zhang H.C., Ye H., Conway B.R., Derian C.K., Addo M.F., Kuo G.H., Hecker L.R., Croll D.R., Li J., Westover L., Xu J.Z., Look R., Demarest K.T., Andrade-Gordon P., Damiano B.P., Maryanoff B.E. 3-(7-Azaindolyl)-4-arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3. Bioorg. Med. Chem. Lett. 2004, 14:3245-3250.